Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Drug Profile

Research programme: cancer therapeutics and diagnostic agents - Siamab Therapeutics

Alternative Names: Anti-glycan antibodies; Anti-Neu5Gc antibodies - Sialix; Anti-Sialyl-Tn anti-CD3 bispecific antibodies; Anti-Sialyl-Tn antibodies; Anti-STn antibodies; ST1 antibody drug conjugate programme

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Sialix
  • Developer Massachusetts General Hospital; Siamab Therapeutics
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Drug conjugates
  • Mechanism of Action Polysaccharide inhibitors; Sialosyl Tn antigen inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Research Cancer

Most Recent Events

  • 08 Mar 2017 Early research in Cancer (Diagnosis) in USA
  • 08 Mar 2017 Preclinical trials in Breast cancer in USA (SCl), before March 2017
  • 08 Mar 2017 Pharmacodynamics data from a preclinical studies in Breast and Colon cancer released by Siamab Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top